{‘She has little expertise’: this US medical community braces for Høeg's appointment at the Food and Drug Administration.

While the US proceeds with unprecedented changes to its vaccination guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines during the global health crisis and has concentrated on possible deaths following COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Immunization Program

Health officials planned to announce radical changes to the childhood immunization program recently, bringing the US with the Danish national calendar, according to reports – a substantial departure that would place the US out of step with a large portion of the global community with no evidence for improved outcomes. The announcement has been delayed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to address the audience at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to run the office this year.

A Shift at the FDA

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics centers as Høeg and Prasad solidify control at the regulatory agency – and it signals a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric vaccine recommendations in the US so as to align more in line with Denmark, a country with comprehensive healthcare and a citizenry approximately the size of Wisconsin’s.

So far statements, she has continued to focus on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no obvious background in pharmaceutical research, oversight or management, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the CDER, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous heads of the center would “grasp legal statutes and the research of medication creation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that previous people who headed CBER have had.”

The drug center has an enormous workload at the agency, she emphasized.

“The public just focuses on the innovative therapies, but the generic drug division authorizes thousands of generic medications. There is also a biosimilars division, over-the-counter program and more, and each of these have to be managed,” Dr. Woodcock said. “The thing you neglect, that is the part that I always told people is going to bite you.”

Additionally, a major administrative aspect to the job, which supervises over 5,000 employees. “It’s a massive leadership role, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Controversial Policies

Regarding questions about Dr. Høeg's qualifications and whether this selection signifies increased cooperation among agency officials on immunizations, a representative stated that the “questions are based on incorrect presumptions”.

“Her experience aligns with the functions of her job,” the official explained, citing the time Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious expedited therapy clearance system that allegedly worried her former heads. “By what process are these medications being selected for this expedited pathway? Who makes the choices?” Howard asked. “There is a lot of confidentiality happening at the agency right now.”

In general, he said, “the FDA appears to be shifting towards more relaxed oversight of most medications, aside from vaccines.”

Public Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if troubling, track record, Howard observe. She released a study using non-validated volunteer-provided data to assess the frequency of myocarditis after Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the current administration featured revising rules for novel immunizations and halting “non-essential” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has according to sources proposed excluding adolescent males from getting Covid vaccinations.

“She is an thorough ideologue who starts off with her preconceived notions and tailors the evidence to accommodate the evidence in a highly misleading, fraudulent manner,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|